FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

AMT Designation Program Guidance

FDA publishes a guidance with recommendations for participating in the agencys Advanced Manufacturing Technologies Designation Program.

latest-news-card-1
Human Drugs

ICH E11A Pediatric Extrapolation Guidance

FDA publishes the International Council on Harmonization E11A Pediatric Extrapolation guidance.

latest-news-card-1

ICH Clinical Practice Guide Annex

FDA publishes Annex 2 of the International Council on Harmonization Good Clinical Practice guidance.

latest-news-card-1
Human Drugs

Brands International Limits, Delays Inspection: FDA

FDA warns a Canadian Brands International facility about limiting and delaying an inspection that also identified CGMP violations.

latest-news-card-1
Human Drugs

NEWSROOM CLOSED FOR THE HOLIDAYS

FDA Webview closes its newsroom for the end-of-year Holiday Season, reopening Thursday, Jan 2, 2025.

latest-news-card-1
Medical Devices

Zimmer Biomet Stemless Shoulder System

FDA clears a Zimmer Biomet 510(k) for the OsseoFit Stemless Shoulder System for total shoulder replacement.

latest-news-card-1
Human Drugs

CDER Right-to-Try Summaries Can Go Thru Portal

CDER updates its CDER NextGen Portal to allow Right to Try annual summary submissions for CDER-regulated products.

latest-news-card-1
Human Drugs

Guide on Tech Specs for NASH Drug Data Sets

FDA posts a final guidance entitled Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steato...

latest-news-card-1
Human Drugs

FDA Promotes Centralized Statistical Trial Monitoring

FDA encourages drug sponsors to use centralized statistical monitoring to help keep an eye on clinical trial integrity issues.

latest-news-card-1
Human Drugs

McKinsey & Co. Pays $650 Million in Opioid Case

McKinsey & Co. agrees to pay $650 million to settle both criminal and civil investigations into its advisory work with Purdue Pharma and the marketing...